AbbVie's growth prospects remain strong despite the impending decline in revenue from Humira. Click here to read more on why I rate ABBV stock as a Buy.

AbbVie Inc., one of the leaders ... More Challenges Await AbbVie Following A Disappointing Quarter. Jul. 14, ... So, except for Q1 2023, the company's R&D spending averaged $1.65 billion, ...

We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha said.

AbbVie is also advancing its collaborations with other companies. With REGENXBIO, AbbVie is developing a gene therapy for two major eye diseases, with pivotal trial results expected in 2026.

AbbVie ends a six-day losing streak with a 0.88% gain, though concerns over increased R&D costs and earnings revisions continue to weigh on investor sentiment.

AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing the impact of $82 million in milestones, and research and development expenses related to acquisitions. The drugmaker ...

AbbVie, known for its strong presence in immunology and oncology, has demonstrated resilience in the face of Humira’s patent expiration. The company reported robust financial results in the fourth ...

AbbVie Ventures knows that challenge intimately, and leverages AbbVie’s in-house expertise as well as its network of third parties to help biotechs work through any hurdles they face.

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion ...